Persephone Biosciences Competitors and Similar CompaniesClear all

Persephone Biosciences's competitors and similar companies include Loxo Oncology, Chugai Pharmaceutical, Epizyme and Janssen.

	Persephone Biosciences Persephone Biosciences is a company developing microbial cell therapies for cancer.	Loxo Oncology Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.	Chugai Pharmaceutical Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases.	Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.	Janssen Janssen is a company providing prescription pharmaceutical products.
Founding Date	Founding Date 2017	Founding Date 2013	Founding Date 1925	Founding Date 2007	Founding Date 1953
Type	Type Private	Type Subsidiary	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare artificial intelligence biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma
Locations	Locations HQ	Locations Stamford, US HQ Alcobendas, ES Boulder, US New York, US South San Francisco, US	Locations Chuo City, JP HQ Guangzhou Shi, CN Taizhou, CN Puteaux, FR Frankfurt Am Main, DE Singapore, SG see more	Locations Cambridge, US HQ	Locations Raritan, US HQ Vienna, AT Prague, CZ Espoo, FI Budapest, HU Oslo, NO Belgrade, RS see more
Employees	Employees 278% increase	Employees 65610% decrease	Employees 7,778	Employees 20364% increase	Employees 17,3684% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 78.7 b	Valuation ($) 250.8 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥1.3t (FY, 2025)	Revenue (est.) $37.4m (FY, 2021)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥363.7b (FY, 2025)	Cost of goods $10.5m (FY, 2021)	Cost of goods N/A
Net income	Net income N/A	Net income ($148.9m) (FY, 2017)	Net income ¥434b (FY, 2025)	Net income ($251.1m) (FY, 2021)	Net income N/A
Funding
Total funding raised	Total funding raised $ 120k	Total funding raised $ 57m	Total funding raised N/A	Total funding raised $ 51.5m	Total funding raised N/A